查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631145

異位性皮膚炎治療藥物市場規模、佔有率、趨勢分析報告：按藥物類別、給藥途徑、分銷管道、地區、細分市場預測，2025-2030年

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids. Biologics), By Route Of Administration (Topical, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

異位性皮膚炎治療藥物市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球異位性皮膚炎治療市場預計將達到298.8億美元。

預計2025年至2030年複合年成長率為9.02%。由於全球異位性皮膚炎盛行率不斷上升、認知不斷提高以及對治療的高需求等因素，異位性皮膚炎（AD）治療市場預計將出現成長機會。此外，不斷推出創新產品佔領市場，是企業贏得市場佔有率、維持主導地位的關鍵策略。

越來越多的高效且副作用較少的產品正在研發中，預計將推動市場的發展。例如，預計2020年至2029年間將有11種治療異位性皮膚炎的新藥上市。其中包括以下藥物類別： Janus激酶 (JAK) 抑制劑、磷酸二酯酶-4 (PDE-4) 和白細胞介素-4&-13 (IL-4/13)。這些新藥的推出將改善重度和中度 AD 患者的生活品質並擴大治療選擇。

簡審類等監管支持預計將加速 AD 的研究和開發。例如，Demira 的 lebrikizumab 獲得了簡審類。此外，2020 年 10 月，Forte Biosciences, Inc. 的藥物 FB-401 獲得 FDA 的簡審類。因此，公司對研發的興趣增加預計將推動市場成長。

增加資金和積極主動的政府舉措來研究和開發異位性皮膚炎新治療方法將支持該地區的成長。公共和私人組織之間的合作預計將提高世界各地消費者的意識。例如，2022年6月，大塚製藥株式會社（大塚控股）宣佈在日本推出AD治療藥物Moiselt軟膏（通用名：difamilast）。該藥是一種非類固醇外用磷酸二酯酶 4 型抑制劑。

在日本，日本皮膚病學會 (JDA) 制定了 AD 指南。該指南於2020年進行了修訂，不僅規定了診斷標準，還規定了治療方法。例如，與發炎相關的 AD 可採用外用皮質類固醇和Tacrolimus治療。這使得更容易系統地治療患者並提高治療效果。

特應性皮膚炎治療藥物市場報告亮點

  • 生技藥品領域佔市場主導地位，2024年佔全球銷售額的38.07%。由於高功效、產品核可增加以及針對異位性皮膚炎的強大生物生物製藥管道的可用性，對生物製藥的需求增加推動了生物製藥行業的成長。
  • 外用藥物細分市場佔據主導地位，2024 年市場佔有率為 39.73%。除了局部治療的安全性和有效性外，其高處方率和實惠的價格也對其廣泛使用做出了重大貢獻。
  • 2024年，醫院藥局細分市場佔61.11%的重要市場佔有率。許多患有中度至重度異位性皮膚炎的患者需要處方箋藥，這些藥物通常在醫院藥房更容易買到。
  • 2024年北美異位性皮膚炎治療市場佔45.12%。這是由於生物製藥和局部治療的高採用率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 異位性皮膚炎治療藥物市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 異位性皮膚炎治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章 異位性皮膚炎治療藥物市場：依藥物類別估計與趨勢分析

  • 全球異位性皮膚炎藥物市場：按藥物類別分類的儀表板
  • 全球異位性皮膚炎治療藥物市場：依藥物類別波動分析
  • 按藥品類別分類的收益
  • 皮質類固醇
  • Calcineurin抑制劑
  • PDE4抑制劑
  • 生物製藥
  • 其他

第5章 異位性皮膚炎治療藥物市場：依給藥途徑估計與趨勢分析

  • 全球異位性皮膚炎藥物市場：按給藥途徑分類的儀表板
  • 全球異位性皮膚炎治療藥物市場：依給藥途徑波動分析
  • 按管理途徑分類的收益
  • 局部的
  • 胃腸外的
  • 口服

第6章 異位性皮膚炎治療藥物市場：依分銷管道估算與趨勢分析

  • 全球異位性皮膚炎治療藥物市場：按分銷管道分類的儀表板
  • 全球異位性皮膚炎治療藥物市場：按分銷管道波動分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥房
  • 其他藥局

第7章 異位性皮膚炎治療藥物市場：區域估計與趨勢分析

  • 區域儀表板
  • 市場規模、預測與趨勢分析（2018-2030）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Pfizer Inc.
    • Sanofi
    • AbbVie Inc.
    • GALDERMA LABORATORIES, LP
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.
    • LEO Pharma Inc.
    • Otsuka Pharmaceutical Co., Ltd
    • Novartis AG
    • Incyte Corporation
Product Code: GVR-2-68038-546-5

Atopic Dermatitis Drugs Market Growth & Trends:

The global atopic dermatitis drugs market size is expected to reach USD 29.88 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.02% from 2025 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights:

  • The biologics segment dominated the market and accounted for 38.07% of the global revenue in 2024. The growth of the biologics segment is augmented by rising demand for biologics due to high efficacy, rising product approvals, and availability of a robust pipeline of biologic drugs for atopic dermatitis.
  • Topical segment dominated the market with a market share of 39.73% in 2024. The high prescription rates and affordability of medications, combined with the safety and efficacy of topical treatments, contribute significantly to their widespread use.
  • The hospital pharmacies segment held a considerable market share of 61.11% in 2024. Many patients with moderate to severe atopic dermatitis require prescription medications, which are often more readily available through hospital pharmacies.
  • The North America atopic dermatitis drugs market accounted for 45.12% share in 2024. This can be attributed to the high adoption rates of biologics and topical treatments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Route of Administration outlook
    • 2.2.2. Route of administration and distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of atopic dermatitis
      • 3.2.1.2. Rising awareness about disease
      • 3.2.1.3. Technological advancement
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations pertaining to drug approval
  • 3.3. Atopic Dermatitis Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Atopic Dermatitis Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Atopic Dermatitis Drugs Market: Drug Class Dashboard
  • 4.2. Global Atopic Dermatitis Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Atopic Dermatitis Drugs Market By Drug Class, Revenue
  • 4.4. Corticosteroids
    • 4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Calcineurin Inhibitors
    • 4.5.1. Calcineurin Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. PDE4 Inhibitors
    • 4.6.1. PDE4 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Biologics
    • 4.7.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Atopic Dermatitis Drugs Market: Route of Administration Dashboard
  • 5.2. Global Atopic Dermatitis Drugs Market: Route of Administration Movement Analysis
  • 5.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Topical
    • 5.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Parenteral
    • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oral
    • 5.6.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Atopic Dermatitis Drugs Market: Distribution Channel Dashboard
  • 6.2. Global Atopic Dermatitis Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other Pharmacies
    • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Pfizer Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Sanofi
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. AbbVie Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GALDERMA LABORATORIES, L.P.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Eli Lilly and Company
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Regeneron Pharmaceuticals Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. LEO Pharma Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Otsuka Pharmaceutical Co., Ltd
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Novartis AG
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Incyte Corporation
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Mexico atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Europe atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Germany atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 Germany atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 UK atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 UK atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 France atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 France atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Italy atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Italy atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Spain atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Spain atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Denmark atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Sweden atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Norway atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Norway atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45 Aisa Pacific atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 China atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 China atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 China atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Japan atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Japan atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Japan atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 India atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 India atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 India atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 South Korea atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 South Korea atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 South Korea atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Australia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 Australia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Australia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Thailand atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Thailand atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Thailand atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 Latin America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 65 Latin America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Latin America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 67 Latin America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 68 Brazil atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 Brazil atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Argentina atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Argentina atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Argentina atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 MEA atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 76 MEA atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 MEA atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 South Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 South Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 South Africa atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 UAE atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 UAE atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 UAE atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Kuwait atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Kuwait atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Kuwait atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Atopic dermatitis drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Atopic dermatitis drugs market segment snapshot
  • Fig. 10 Atopic dermatitis drugs market competitive snapshot
  • Fig. 11 Atopic dermatitis drugs market driver impact
  • Fig. 12 Atopic Dermatitis Drugs market restraint impact
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Value chain analysis
  • Fig. 16 Atopic dermatitis drugs market: Drug class outlook and key takeaways
  • Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
  • Fig. 18 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Calcineurin Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 PDE4 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Atopic Dermatitis Drugs market: Route of administration outlook and key takeaways
  • Fig. 24 Atopic Dermatitis Drugs market: Route of administration movement analysis
  • Fig. 25 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Atopic Dermatitis Drugs market: Distribution channel outlook and key takeaways
  • Fig. 29 Atopic Dermatitis Drugs market: Distribution channel movement analysis
  • Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Global Atopic Dermatitis Drugs market: Regional movement analysis
  • Fig. 34 Global Atopic Dermatitis Drugs market: Regional outlook and key takeaways
  • Fig. 35 Global Atopic Dermatitis Drugs market share and leading players
  • Fig. 36 North America, by country
  • Fig. 37 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. key country dynamics
  • Fig. 39 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada key country dynamics
  • Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico key country dynamics
  • Fig. 43 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Argentina key country dynamics
  • Fig. 78 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 South Africa key country dynamics
  • Fig. 81 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Saudi Arabia key country dynamics
  • Fig. 83 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 UAE key country dynamics
  • Fig. 85 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait key country dynamics
  • Fig. 87 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Market share Analysis of key market players, 2024